Polysaccharide Patents (Class 514/54)
  • Patent number: 10266511
    Abstract: The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: April 23, 2019
    Assignee: EUCLISES PHARMACEUTICALS, INC.
    Inventors: John J. Talley, Eduardo J. Martinez
  • Patent number: 10245280
    Abstract: Use of hyaluronic acid as the sole active ingredient for preparing compositions in particular for topical use for treating oral cavity aphthas.
    Type: Grant
    Filed: June 23, 2004
    Date of Patent: April 2, 2019
    Assignee: Bioplax Limited
    Inventor: Franco Macchi
  • Patent number: 10232007
    Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: March 19, 2019
    Assignee: WORLD FORCE TECHNOLOGIES, LLC
    Inventors: Thomas W. Konowalchuk, Jack Konowalchuk
  • Patent number: 10231990
    Abstract: The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: March 19, 2019
    Assignee: Horus Pharma
    Inventors: Claude Claret, Martine Claret, Carole Gard
  • Patent number: 10220113
    Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: March 5, 2019
    Assignee: Allergan Industrie, SAS
    Inventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost
  • Patent number: 10206944
    Abstract: Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: February 19, 2019
    Assignee: ALTERGON S.A.
    Inventors: Mario De Rosa, Chiara Schiraldi
  • Patent number: 10206895
    Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: February 19, 2019
    Assignee: ARBOR PHARMACEUTICALS, INC.
    Inventors: H. Greg Thomas, Jeffrey S. Kiel
  • Patent number: 10201561
    Abstract: An object of the present invention is to provide an antiviral fiber assembly in which an antiviral agent is retained with chemical stability over a long period of time, and which is gentle to the human body. A further object of the present invention is to provide a fiber assembly with cellulose sulfate that can exhibit sufficient antiviral activity over a long period of time. Further, another object of the present invention is to provide a textile product obtained using such a fiber assembly. The present invention provides a fiber assembly with cellulose sulfate, wherein the hyaluronidase inhibitory activity is 50% or higher; and a process for producing a fiber assembly with cellulose sulfate, including treating a fiber assembly with an aqueous cellulose sulfate solution and drying, then treating the same with a pH buffer solution and drying.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: February 12, 2019
    Assignees: ES FiberVisions CO., LTD., ES FiberVisions Hong Kong Limited, ES FiberVisions LP, ES FiberVisions ApS
    Inventors: Yoshiko Watanabe, Kazuyuki Sakamoto
  • Patent number: 10195239
    Abstract: Disclosed herein is an extract obtainable from Trigonella foenum-graecum. In particular, the extract is obtainable by a process comprising the steps of preparing a mixture of a plant material obtained from Trigonella foenum-graecum and liquid, incubating said mixture for at least 3 hours, heating of said mixture, and recovering a liquid extract from mixture. The extract is useful in the manufacture of various types of compositions, such as pharmaceutical compositions, disinfectant or preservation agents. The pharmaceutical may be used for the treatment or prevention of an inflammatory disease or an infectious condition.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: February 5, 2019
    Assignee: V-BIOTEK HOLDING APS
    Inventor: Jens Steen Olsen
  • Patent number: 10195312
    Abstract: A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.
    Type: Grant
    Filed: February 8, 2017
    Date of Patent: February 5, 2019
    Inventor: Xin Ji
  • Patent number: 10172884
    Abstract: This document relates to bi-carbonate-buffered dialysis solutions with physiological phosphate content and increased stability. The solutions include an organic ester of phosphoric acid, calcium ions and/or magnesium ions, and optionally additional electrolytes, buffers and glucose in physiologically effective concentrations.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: January 8, 2019
    Assignee: Fresenius Medical Care Deutschland GmbH
    Inventors: Jochen Huppert, Pascal Mathis, Robert Berlich, Robert Pohlmeier
  • Patent number: 10173976
    Abstract: Described herein are compositions and compounds having one or more aziridinyl groups, and methods of making the same. The compounds can also have one or more nitrogen atoms that each can be positively charged. The composition and compounds can inactivate one or more nucleic acid molecules (e.g. a DNA and/or a RNA from a pathogen) in a sample. The sample can comprise a blood or blood product (e.g., donated blood). The compositions and compounds can inactivate any nucleic acid present in a blood or blood product, thereby making the blood or blood product safe for use (e.g., in a transfusion).
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: January 8, 2019
    Assignee: ZATA PHARMACEUTICALS, INC.
    Inventor: David R. Tabatadze
  • Patent number: 10143221
    Abstract: The invention relates to a novel sweet-tasting refreshing beverage, which is free of phosphoric acid and instead contains at least 0.3% by weight/volume of gluconic acid, which is low in minerals, specifically contains less than 250 mg/liter of minerals, which is low in sugar, specifically contains at most 2.5% by weight/volume of sugar, wherein these sugars comprise at least 10% weight/weight galactose and in addition a proportion of isomaltulose and/or tagatose, and which has a glycemic index of at most 35 (GI<35).
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: December 4, 2018
    Inventor: Johannes Coy
  • Patent number: 10130601
    Abstract: The present invention provides use of a composition comprising fish oil with low totox value and juice in an oil-in-water emulsion in treatment/resolution of inflammation and/or diseases wherein an underlying cause is inflammation. The invention encompasses further said composition comprising acetylsalicylic acid and/or derivatives and/or analogous thereof. Further the present invention is related to the combined use of a composition of the invention and a therapeutic agent for the treatment of inflammatory diseases or diseases wherein an underlying cause is inflammation.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: November 20, 2018
    Assignee: Smartfish AS
    Inventor: Janne Sande Mathisen
  • Patent number: 10123535
    Abstract: The present invention relates to methods for modifying an agricultural crop comprising treating the agricultural crop with a composition comprising a xyloglucan endotransglycosylase and (a) a polymeric xyloglucan and a functionalized xyloglucan oligomer comprising a chemical group; (b) a polymeric xyloglucan functionalized with a chemical group and a functionalized xyloglucan oligomer comprising a chemical group; (c) a polymeric xyloglucan functionalized with a chemical group and a xyloglucan oligomer; (d) a polymeric xyloglucan, and a xyloglucan oligomer; (e) a polymeric xyloglucan functionalized with a chemical group; (f) a polymeric xyloglucan; (g) a functionalized xyloglucan oligomer comprising a chemical group; or (h) a xyloglucan oligomer, or (a-h) without a xyloglucan endotransglycosylase, in a medium under conditions leading to a modified agricultural crop possessing an improved property compared to the unmodified agricultural crop.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: November 13, 2018
    Assignee: Novozymes A/S
    Inventors: Alex Berlin, Jason Quinlan, Romil Benyamino
  • Patent number: 10117822
    Abstract: The present invention relates, in one aspect, to the use as dermal filler of a cross-linked biopolymer compatible with the tissues of the human organism based on hyaluronic acid cross-linked with urea. The biopolymer of hyaluronic acid and urea may be applied or injected in a soft tissue of human body for tissue augmentation.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: November 6, 2018
    Assignee: I.R.A. ISTITUTO RICERCHE APPLICATE S.R.L.
    Inventors: Ugo Raffaello Citernesi, Lorenzo Beretta, Lorenzo Citernesi
  • Patent number: 10098906
    Abstract: The growth and/or proliferation of mammalian cells are modulated by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. Sulfated polysaccharides, preferably glycosaminoglycans, can be used as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. The physical interaction between platelets (thrombocytes) and the surface of the cells can be modulated in vitro in order to modulate cell proliferation. Inhibition of the interaction between the cell surface and platelets can inhibit cell growth, and enhancement of the interaction between platelets and the surface of the cell can enhance cell growth.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: October 16, 2018
    Assignee: CELL RECEPTOR AG
    Inventor: Hans-Ake Fabricius
  • Patent number: 10098961
    Abstract: An injectable hyaluronic acid composition including a hyaluronic acid; a local anesthetic selected from the group of amide and ester type local anesthetics or a combination thereof; and an ascorbic acid derivative in an amount which prevents or reduces the effect on the viscosity and/or elastic modulus G? of the composition caused by the local anesthetic upon sterilization by heat. Further, the medical and non-medical, such as cosmetic, use of such a composition, and a method of manufacturing such a composition.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: October 16, 2018
    Assignee: Q-MED AB
    Inventors: Åsa Wiebensjö, Katarina Edsman
  • Patent number: 10092657
    Abstract: Described herein are compositions that include isolated opsonized soluble ?-glucan, methods of making those compositions and methods of using those compositions.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: October 9, 2018
    Assignee: Biothera, Inc.
    Inventors: Nandita Bose, Anissa S. H. Chan
  • Patent number: 10092528
    Abstract: A zero-calorie to near-zero-calorie snacking product that, when consumed, provides a feeling of fullness prior to absorption of energy-providing food, i.e., pre-absorptive satiation is disclosed. The snacking product is based on the stimulation of vagal nerve endings in the gastro-intestinal tract by encapsulated capsaicin. The encapsulation of capsaicin avoids the burning sensation in the mouth which may be objectionable to some consumers.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 9, 2018
    Assignee: Altria Client Services LLC
    Inventors: Maria Gogova, Georgios D. Karles, Gerd Kobal, Munmaya K. Mishra
  • Patent number: 10087225
    Abstract: A pharmaceutical formulation comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, up to 5% w/w solids before drying, a component selected from the group consisting of glycerin, lactose, and trehalose and excluding mannitol, and a pharmaceutically acceptable carrier, that preserves stability and bioavailability of the polypeptide is provided.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: October 2, 2018
    Assignee: MOERAE MATRIX, INC.
    Inventors: Cynthia Lander, Colleen Brophy, Caryn Peterson
  • Patent number: 10086111
    Abstract: This invention relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition wherein the polysaccharide may be succinochitosan glutamate. This invention also relates to a biomaterial comprising an injectable bioresorbable polysaccharide composition in which resorbable particles may be in suspension, the said particles comprising or consisting essentially of chitin and/or chitosan, which may be free of any additional formulation modifying agents, and a process for manufacturing the same. This invention also relates to a medical device including said biomaterial and to a method of repair or treatment including the filling of cavities in the human face or body.
    Type: Grant
    Filed: April 5, 2016
    Date of Patent: October 2, 2018
    Assignee: Cutanea Life Sciences, Inc.
    Inventors: Elisabeth Laugier, Frank Gouchet, Bernard Grandmontagne
  • Patent number: 10064889
    Abstract: The present invention discloses a mercapto-modified biocompatible macromolecule derivative with a low degree of modification. The mercapto-modified biocompatible macromolecule derivative not only maintains the initial structure, physiological function and biocompatibility as much as possible, but also allows the preparation of the biocompatible macromolecule cross-linked material with a low degree of cross-linking through the effectively chemical cross-linking with the introduced mercapto group. The present invention further discloses a disulfide-bond cross-linked biocompatible macromolecule material with a very low degree of cross-linking.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 4, 2018
    Assignee: Bioregen Biomedical (Changzhou) Co., Ltd.
    Inventors: Xiaozheng Shu, Weiping Zhong, Yunyun Wang, Meixia Yu
  • Patent number: 10064791
    Abstract: The present invention relates to a cosmetic composition, in the form of an oil-in-water emulsion, characterized in that it comprises a 2-acrylamido-2-methylpropanesulfonic acid polymer, a copolymer of 2-acrylamido-2-methylpropanesulfonic acid and of an alcohol(meth)acrylate, and a hydrophobic-modified inulin-based amphiphilic polymer, the globules of the said emulsion having a mean size ranging from 15 to 500 microns and the oily phase being present in an amount of less than 35% by weight relative to the total weight of the composition. The invention also relates to a cosmetic process for treating keratin materials.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: September 4, 2018
    Assignee: L'OREAL
    Inventor: Fanny Plismy Juquel
  • Patent number: 10058566
    Abstract: A polygulonic acid sulfate or pharmaceutically acceptable salt thereof, preparation method therefor and use thereof in the preparation of tumor growth and/or metastasis inhibitors are disclosed. The polygulonic acid sulfate or pharmaceutically acceptable salt thereof of the present invention can be used in the preparation of any one or more of tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerizing factor activity inhibitors and actin-aggregation inhibitors.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: August 28, 2018
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
    Inventors: Jian Ding, Jing Ai, Yi Chen, Xun Huang
  • Patent number: 10047172
    Abstract: A process for manufacturing a cross-linked hyaluronic acid (HA) containing a functionalizing group including the step of reacting HA with a mixture of: (i) a first cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, and (ii) a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a second cross-linking agent selected from the group of bifunctional epoxides and polyfunctional epoxides, to obtain a cross-linked HA containing the functionalizing group. The process provides a cross-linked hyaluronic acid (HA) containing a functionalizing group. The process utilizes a functionalized agent of a functionalizing group coupled via a 1,2,3-triazole linkage to a cross-linking agent.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: August 14, 2018
    Assignee: GALDERMA S.A.
    Inventor: Jean-Guy Boiteau
  • Patent number: 10034895
    Abstract: At equimolar concentrations, D-lactic acid dimer is more cytotoxic than L-lactic acid when directly applied to human HeLa cells in culture. The cytotoxicity of D-lactic acid dimer is an independent effect exclusive of the lower pH when applied to cancer cells in culture. At equimolar concentrations, D-lactic acid dimer is less cytotoxic than L-lactic acid when applied to normal human fibroblasts in culture. D-lactic acid dimer is cytotoxic when applied to human retinoblastoma cells in culture in a dose-dependent fashion. The experimental data supports the cytotoxic mechanism of D-lactic acid dimer via the Warburg effect.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 31, 2018
    Inventors: Joel Steven Goldberg, Joe Brice Weinberg
  • Patent number: 10030274
    Abstract: This invention provides a means for screening for lactic acid bacteria having immunoregulatory functions in a simple and rapid manner. This invention provides a method for screening for or producing lactic acid bacteria having immunoregulatory functions comprising determining the number of the test lactic acid bacteria bound to the uromodulin (Umod) protein, lactic acid bacteria obtained by such method, and an immunoregulatory composition comprising such lactic acid bacteria.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: July 24, 2018
    Assignee: ASAHI GROUP HOLDINGS, LTD.
    Inventors: Sae Hyakutake, Tatsuhiko Hirota, Shinji Fukuda, Hiroshi Ohno, Naoyuki Yamamoto
  • Patent number: 10029015
    Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: July 24, 2018
    Assignee: ASCENDIS PHARMA A/S
    Inventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
  • Patent number: 9993417
    Abstract: The present invention relates to a combination comprising a hyaluronic acid or a salt thereof and a sulphated polysaccharide of which the molecular weight is between 5 and 25 kDa, which is of use in particular for combating the signs of skin ageing or for treating and healing skin wounds.
    Type: Grant
    Filed: April 30, 2015
    Date of Patent: June 12, 2018
    Assignee: PIERRE FABRE DERMO-COSMETIQUE
    Inventors: Stéphane Poigny, Hélène Hernandez-Pigeon, Jean-Hilaire Saurat, Gürkan Kaya
  • Patent number: 9994603
    Abstract: The present invention relates to a process for an epimerization of a saccharide in a microdevice consisting of a network of micron-sized channels in presence of molybdenum containing catalyst. It further relates to the use of a microdevice consisting of a network of micron-sized channels for the epimerization reaction of saccharides and the oligomerization of the thus obtained epimerized saccharide, preferably into manno-oligosaccharides.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: June 12, 2018
    Assignee: CARGILL, INCORPORATED
    Inventor: Bruno Frédéric Stengel
  • Patent number: 9981066
    Abstract: The present invention provides anti-thrombogenic compositions, including anti-thrombogenic vascular grafts. In certain embodiments, the compositions comprise decellularized tissue coated with an anti-thrombogenic coating. The present invention also provides methods of preparing anti-thrombogenic compositions and methods of treatment comprising implanting the anti-thrombogenic compositions into a subject in need thereof.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: May 29, 2018
    Assignee: Yale University
    Inventors: Sashka Dimitrievska, Laura Niklason
  • Patent number: 9974802
    Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-?-L-arabinose (Ara) residues.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: May 22, 2018
    Assignee: Galectin Therapeutics, Inc.
    Inventors: Eliezer Zomer, Peter G. Traber, Anatole A. Klyosov, Elena Chekhova
  • Patent number: 9968910
    Abstract: Compositions are disclosed herein comprising poly alpha-1,3-glucan or poly alpha-1,3-1,6-glucan polymer having an open-cell pore structure with an average pore size of about 100 nm to about 3000 nm in diameter. Such polymers have enhanced aqueous liquid absorption capacity, and can be comprised in various products having aqueous liquid absorption function. Methods of preparing glucan polymers of the compositions provided herein are also disclosed.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: May 15, 2018
    Assignee: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Natnael Behabtu, Rakesh Nambiar
  • Patent number: 9969763
    Abstract: The present invention relates to carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles useful as vaccine adjuvants of formula 1 The present invention also provides process for preparation of carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles. The carbohydrate-di and tri lipidated cysteine based 1,2,3-triazoles as vaccine adjuvants are useful in formulations for therapeutic and prophylactic vaccines against bacterial, viral, protozoan infections and cancer.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 15, 2018
    Assignee: Council of Scientific and Industrial Research
    Inventors: Halmuthur Mahabalarao Sampathkumar, Naresh Nalla, Sathyaseelan Sathyabama, Sabbana Surya Vamshi, Bonam Srinivasa Reddy, Veerjala Naveen Kumar
  • Patent number: 9943607
    Abstract: Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: April 17, 2018
    Assignee: Biothera, Inc.
    Inventors: Nandita Bose, Anissa S. H. Chan, Michael E. Danielson, Mary A. Antonysamy, John P. Vasilakos, Keith B. Gorden, Steven M. Leonardo, William J. Grossman
  • Patent number: 9931299
    Abstract: Disclosed herein are inventive stable homogenized biomass hetero-colloids, their production and uses. Such biomass hetero-colloids comprise biomass derived solid particle colloid matter and at least 15% (w/w) biomass derived soluble colloid matter. The novel biomass hetero-colloids provide an inventive approach for the application of biologically active compounds. Bio-actives are made available in an innovative form involving low intervention processing and enhancing the biological availability.
    Type: Grant
    Filed: April 19, 2013
    Date of Patent: April 3, 2018
    Inventor: Othmar Kaeppeli
  • Patent number: 9919081
    Abstract: Embodiments relate to an ophthalmology microscopy-system and a method of operating an ophthalmology microscopy-system which allow for an at least partial or full removal of liquids and gels used in ophthalmology for application in an eye of a patient in an particularly efficient way. Further embodiments relate to a product such as a liquid or a gel usable for an application in an eye of a patient, wherein the product has a high transmittance and, nevertheless, may be made visible particularly well.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: March 20, 2018
    Assignee: CARL ZEISS MEDITEC AG
    Inventors: Anja Seiwert, Christoph Hauger, Roland Guckler, Claude Moissonnier
  • Patent number: 9908947
    Abstract: The present invention discloses a process for the production of chondroitin sulphate with an average molecular weight (Mw) of 10-30 kDa by chemical sulphation starting from an unsulphated chondroitin backbone, obtained in turn by acid hydrolysis of capsular polysaccharide K4 made directly from E. coli strain O5:K4:H4, or directly produced from a genetically modified strain of E. coli. Sulphation of the N-acetyl-D-galactosamine residue at position 4 or 6 takes place simultaneously in the same polysaccharide chain, simulating the sulphation pattern observed in natural chondroitin sulphate, unlike the sulphation obtained with the synthesis methods described to date.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 6, 2018
    Assignee: Gnosis S.p.A.
    Inventors: Davide Bianchi, Marco Valetti, Paola Bazza, Niccolo Miraglia, Ermanno Valoti
  • Patent number: 9901606
    Abstract: A composition includes a Euglena lysate and cellular components and residual media remaining from a fermentation process that produced a Euglena biomass and the Euglena lysate. The cellular components may include one or more beta-glucan polymer chains having a molecular weight of 1.2 to 580 kilodaltons (kDa).
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: February 27, 2018
    Assignee: ALGAEON, INC.
    Inventors: Brad M. Cox, Derek E. Jamrog, Kip R. Zurcher
  • Patent number: 9903876
    Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: February 27, 2018
    Assignee: Bloodworks
    Inventor: James Charles Zimring
  • Patent number: 9898843
    Abstract: When line graphs are displayed on coordinates having a horizontal axis as a time axis and a vertical axis as an axis representing examination values, a line graph is generated in such a manner that data points representing examination data are connected to each other by a line in a case where a time interval between examinations temporally next to each other is less than a maximum line-connection interval for an examination item, and in such a manner that data points representing examination data are not connected to each other in a case where the time interval between examinations temporally next to each other exceeds the maximum line-connection interval for the examination item. Plural line graphs overlapping with each other are displayed on the coordinates.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: February 20, 2018
    Assignee: FUJIFILM Corporation
    Inventor: Shoji Kanada
  • Patent number: 9896561
    Abstract: The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: February 20, 2018
    Assignee: Board of Regents, The University of Texas System
    Inventors: Scott Zawko, Christine Schmidt
  • Patent number: 9889150
    Abstract: The present invention relates to the use of agents (including heparin derivatives) for the prevention and/or treatment of CNS damage.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: February 13, 2018
    Assignees: The University Of Liverpool, The University Court of the University of Glasgow
    Inventors: Jeremy Ewan Turnbull, Scott Ernest Guimond, Sophie Marie Thompson, Susan Carol Barnett, Jennifer Rosemary Higginson
  • Patent number: 9889073
    Abstract: The instant invention relates to a color changing composition in the form of an emulsion comprising, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: —a core comprising one organic material, —at least one layered coating surrounding said core, the layered coating comprising at least one polymer, at least one colorant, and advantageously at least one lipid-based material, b) at least partially neutralized, crosslinked acrylic homopolymers or copolymers preferably in a non-particulate form.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: February 13, 2018
    Assignee: L'OREAL
    Inventors: Audrey Ricard, Micheline El Achkar
  • Patent number: 9885089
    Abstract: High levels of bacterial flagella in a sample such as a gastrointestinal sample and/or low levels of anti-flagella antibodies serve as an indication for metabolic syndrome (such as insulin resistance, hypertension, elevated cholesterol, increased risk for blood clotting, and obesity) with highest levels of adiposity. An intervention that reduces the level and/or activity of flagella in the gastrointestinal tract can mitigate the severity of metabolic syndrome or in protecting against the development of metabolic syndrome.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 6, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Ruth E. Ley, Tyler Cullender
  • Patent number: 9877983
    Abstract: The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g. for disinfection and cleaning purposes.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: January 30, 2018
    Assignee: ALGIPHARMA AS
    Inventors: Edvar Onsoyen, Rolf Myrvold
  • Patent number: 9879097
    Abstract: When manufacturing a sugar chain compound having an activating group, there was a problem with the ammonium carbonate method that is the conventional technology that during the process of introducing an amino group at the reducing terminal of the sugar chain, the unit sugar located at the reducing terminal of the sugar chain is subjected to ring-opening, thus causing a mixture of ? and ? anomers to be produced.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: January 30, 2018
    Assignee: Glytech, Inc.
    Inventor: Takefumi Murase
  • Patent number: 9879124
    Abstract: A process for producing a water-insoluble shaped material, including a step of treating a raw material shaped material containing a water-soluble salt of a polyanionic polysaccharide with a treatment liquid containing an acid anhydride to insolubilize the raw material shaped material in water, and the process makes it possible to simply produce a water-insoluble shaped material in which intrinsic characteristics of the polyanionic polysaccharide being a raw material are retained, which has a high safety in that a chemical crosslinking agent is not required, and which is useful as a medical material, a food material, a cosmetic material, and the like.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: January 30, 2018
    Assignee: DAINICHISEIKA COLOR & CHEMICALS MFG. CO., LTD.
    Inventors: Yasuyuki Isono, Yasuharu Noishiki
  • Patent number: 9855367
    Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: January 2, 2018
    Assignee: Allergan Industrie, SAS
    Inventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost